ARTICLE | Clinical News
Alteon preclinical data
January 29, 2001 8:00 AM UTC
ALT researchers and colleagues published in Diabetologia that ALT-946 was more potent that ALT's lead product, Pimagedine aminoguanidine, in preventing advanced glycosylation end product protein cross...